Clinical Trials Logo

Filter by:
NCT ID: NCT03370380 Active, not recruiting - Clinical trials for Pigment Epithelial Detachment

Aflibercept in Patients With Pigment Epithelial Detachments (PED)

Start date: April 2015
Phase: N/A
Study type: Observational

Uncontrolled single site non randomized non interventional study to determine the safety and efficacy of intravitreal injections of Aflibercept in patients with recent vision loss due to retinal pigment epithelial detachment secondary to AMD

NCT ID: NCT03369938 Recruiting - Heart Failure Clinical Trials

Exercise Training in Patients With Left Ventricular Assist Device

Ex-VAD
Start date: December 4, 2017
Phase: N/A
Study type: Interventional

The objective of the study is to test whether 12 weeks of structured supervised exercise training on top of usual care improves functional capacity in patients with end-stage heart failure with continuous flow left ventricular assist device (LVAD).

NCT ID: NCT03369665 Not yet recruiting - Multiple Sclerosis Clinical Trials

Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS)

Start date: February 15, 2018
Phase: Phase 4
Study type: Interventional

The main purpose of the study is to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS) subjects treated with Mavenclad® for 2 years (24 months).

NCT ID: NCT03369210 Recruiting - Anemia Clinical Trials

Liberal Transfusion Strategy in Elderly Patients

LIBERAL
Start date: December 4, 2017
Phase: Phase 3
Study type: Interventional

In this prospective, multicentre, open, randomised, controlled clinical trial elderly patients (≥ 70 years) undergoing intermediate- or high-risk non-cardiac surgery will be randomised either to a liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)) or restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l). Primary efficacy endpoint: is a composite of death from any cause and anaemia-associated, ischaemic events (defined as acute myocardial infarction, acute ischaemic stroke, acute kidney injury stage III, acute mesenteric ischaemia, acute peripheral vascular ischaemia) within 90 days after surgery.

NCT ID: NCT03368664 Recruiting - Multiple Sclerosis Clinical Trials

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

LemKids
Start date: October 24, 2017
Phase: Phase 3
Study type: Interventional

Primary Objective: To evaluate the efficacy, safety, and tolerability of alemtuzumab (IV) in pediatric patients from 10 to <18 years of age with Relapsing Remitting Multiple Sclerosis (RRMS) who have disease activity on prior Disease Modifying Therapy (DMT). Secondary Objective: To assess the pharmacokinetics (PK), pharmacodynamics (PD), anti-drug antibody (ADA) formation, and potential effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (QoL).

NCT ID: NCT03368040 Recruiting - Clinical trials for Body Temperature Changes

Comparison Between Non-invasive Heat-flux and Invasive Core Temperature Monitoring

Start date: September 2016
Phase: N/A
Study type: Observational

The body core temperature drops during general anesthesia. To maintain homeostasis, patients require warming measures. Different methods to measure body core temperature exist, which are either highly accurate but invasive, or non-invasive but non-accurate. A new monitoring device, Tcore(TM), enables a non-invasive but accurate core temperature assessment. This study is performed to quantify accuracy and bias of the Tcore system in comparison with the blood temperature, which is the gold standard of core temperature measurement.

NCT ID: NCT03367975 Recruiting - Clinical trials for Subarachnoid Hemorrhage

NIRS Monitoring During Intracranial Interventions

NIRS_ICG
Start date: March 2014
Phase: N/A
Study type: Observational

Near infrared spectroscopy is a valuable tool to monitor cerebral oxygenation during intracranial interventions. However, it yields artificial results when the dye indocyanine green (ICG) is applied, which is routinely done for intraoperative angiography. The investigators examine, to what extent and which duration NIRS is disturbed following ICG application.

NCT ID: NCT03366545 Not yet recruiting - Heart Failure Clinical Trials

Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

BIO|STREAM HF
Start date: January 2018
Phase: N/A
Study type: Observational [Patient Registry]

The registry is primarily designed to assess outcome, efficacy and residual safety aspects of CRT based on long-term data from an unselected, real-life clinical set-up. Moreover, the observation of the patient status should help to find possible predictors for HF events and to identify areas of improvement for CRT and for CRT device settings.

NCT ID: NCT03366272 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

NIVEAU
Start date: December 5, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma

NCT ID: NCT03365479 Recruiting - Clinical trials for Pulmonary Hypertension

Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

Primary objective • To evaluate the effect of rapid inhalation of 2.5μgiloprost using the Breelib nebulizer on pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension Secondary objectives - To evaluate the effect of rapid iloprost inhalation using the Breelib nebulizer on mean pulmonary arterial pressure (mPAP), cardiac output (CO), cardiac index (CI), systemic blood pressure, arterial oxygen saturation, heart rate, and pulmonary arterial wedge pressure (PAWP). - To evaluate the safety and tolerability of the rapid iloprost inhalation using the Breelib nebulizer.